세계 혈관조영 장비 시장 규모는 심혈관 질환의 유병률 증가와 최소침습적 진단 절차에 대한 수요 증가로 인해 2025-2032년의 예측 기간 동안 5.77%의 연평균 복합 성장률(CAGR)로 2024년 127억 7,000만 달러에서 2032년에는 200억 달러로 성장할 것으로 예상됩니다. AI 기반 이미징 및 개선된 카테터 기반 시스템과 같은 기술 발전은 진단의 정확성과 효율성을 높입니다. 또한, 신흥국 시장에서의 보급을 뒷받침하는 유리한 상환 정책과 의료 인프라의 확장도 있습니다.
예를 들어, 2024년 8월 미국 Medicare & Medicaid Services(CMS)는 심장 CT 혈관조영술에 대한 상환율 인상을 제안했습니다. 현재 시술 당 약 175달러가 상환되는 CCTA는 급성 및 안정기 관상동맥 질환이 의심되는 환자를 평가하기 위한 1등급 진단 도구로 강력하게 지지받고 있습니다.
세계의 혈관조영 장비 시장에 대해 조사했으며, 시장 개요와 함께 제품 유형별/기술별/시술 유형별/적응증별/용도별/최종사용자별/지역별 동향, 시장 진출 기업 프로파일 등의 정보를 정리하여 전해드립니다.
Global angiography equipment market is projected to witness a CAGR of 5.77% during the forecast period 2025-2032, growing from USD 12.77 billion in 2024 to USD 20 billion in 2032 owing to the rising prevalence of cardiovascular diseases and increasing demand for minimally invasive diagnostic procedures. Technological advancements, such as AI-powered imaging and improved catheter-based systems, enhance diagnostic precision and efficiency. Additionally, favorable reimbursement policies and expanding healthcare infrastructure support widespread adoption across developed and emerging markets.
For instance, in August 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) proposed increased reimbursement rates for cardiac CT angiography procedures, after several years of reduced funding. Currently reimbursing around USD 175 per procedure, CCTA is strongly endorsed as a class 1 diagnostic tool for evaluating suspected coronary artery disease in both acute and stable cases.
Rising Prevalence of Cardiovascular Diseases (CVDs) Boosting Market Growth
The global burden of cardiovascular diseases (CVDs) has been escalating rapidly due to factors like sedentary lifestyles, unhealthy dietary habits, obesity, and increasing rates of diabetes and hypertension. CVDs such as coronary artery disease, heart failure, and stroke have become the leading causes of morbidity and mortality worldwide. This growing prevalence has significantly increased the demand for effective diagnostic and therapeutic procedures to detect and manage vascular abnormalities. Angiography equipment plays a critical role in the early and accurate diagnosis of CVDs by providing detailed imaging of blood vessels and cardiac structures. As governments and healthcare providers emphasize early detection and prevention strategies, angiography systems are increasingly being integrated into hospital diagnostic infrastructures. Moreover, awareness campaigns and improved access to healthcare services in developing regions also encourage patients to undergo diagnostic procedures, further driving the market. With aging populations and rising chronic disease burdens, the global need for angiographic procedures is expected to grow steadily, pushing the demand for technologically advanced and efficient imaging systems across both developed and emerging markets.
For instance, as of October 2024, the Centers for Disease Control and Prevention (CDC) reaffirmed that cardiovascular disease continues to be the primary cause of death among both men and women across most racial and ethnic demographics in the United States. According to the report, one person succumbs to a heart-related condition every 33 seconds in the country.
Technological Advancements in Imaging Systems Rising Market Engagement
Technological innovation has emerged as a major catalyst in transforming the angiography equipment landscape. Modern angiography systems now offer features such as digital flat-panel detectors, 3D rotational angiography, and AI-based image analysis tools, all of which significantly enhance the quality of vascular imaging. These advancements improve diagnostic precision and reduce radiation exposure, ensuring greater safety for patients and medical staff. Integrating hybrid operating rooms and real-time navigation software allows clinicians to make more informed decisions during interventional procedures. Moreover, compact and mobile systems enable angiographic imaging in minimally invasive and ambulatory care settings.
The trend towards digitization, including cloud-based image storage and AI-powered diagnostics, further enhances workflow efficiency and facilitates better patient outcomes. As healthcare systems globally aim to improve diagnostic infrastructure and minimize invasive procedures, the preference for highly advanced angiography systems is rising. These innovations encourage hospitals and imaging centers to replace older equipment with newer, more precise solutions, fueling market expansion across multiple geographies and specialties. For instance, in February 2024, Koninklijke Philips N.V. introduced an upgraded version of its Azurion Image Guided Therapy System, featuring a new neuro biplane configuration. This latest release aims to enhance the speed and precision of neurovascular interventions, offering advanced 2D/3D imaging and improved detector flexibility for superior clinical performance.
Growing Adoption of Magnetic Resonance Angiography (MRA)
Magnetic Resonance Angiography (MRA) has gained considerable traction as a non-invasive, radiation-free imaging modality for evaluating blood vessels. Unlike traditional X-ray or CT angiography, MRA does not require iodinated contrast agents, making it a safer option for patients with allergies or kidney impairments. It is especially useful in diagnosing cerebrovascular diseases, peripheral artery disease, and congenital heart anomalies. The increasing clinical preference for MRA stems from its high soft tissue contrast, multiplanar imaging capabilities, and safety profile, which make it suitable for repeated scans during follow-up evaluations. As advancements in MRI technology continue to improve image resolution and scanning speed, the accuracy and efficiency of MRA have also increased. Healthcare providers are increasingly integrating MRA into routine vascular assessments due to its diagnostic effectiveness and patient comfort. Additionally, with the rise in awareness about radiation risks and demand for non-invasive techniques, MRA is expected to witness sustained adoption.
The shift towards preventive diagnostics and patient-centric care models is further expected to support the growth of this segment within the broader angiography equipment market. A study published in Science Advances in October 2024 highlighted magnetic resonance angiography (MRA) as a crucial diagnostic tool for panvascular conditions. The researchers addressed the limitations of single-modality imaging and introduced dual-modality NaGdF4 nanoparticles that improve MRA sensitivity and enable multi-parameter vascular imaging through combined T1 and T2 contrast effects.
North America Leading the Angiography Equipment Market
North America continues to lead the global angiography equipment market, driven by a combination of advanced healthcare infrastructure, high healthcare expenditure, and strong demand for innovative diagnostic tools. The region sees a high incidence of cardiovascular conditions, largely due to aging populations, sedentary lifestyles, and dietary factors. This has increased the adoption of angiographic procedures for both diagnostic and interventional purposes. The presence of leading market players and robust R&D activities in the United States and Canada have enabled the early adoption of cutting-edge imaging technologies. Additionally, favorable reimbursement policies for diagnostic imaging and interventional cardiology procedures enhance patient access and encourage healthcare providers to invest in premium angiography systems. Regional healthcare systems also benefit from the widespread use of electronic health records and AI-based diagnostic platforms, improving workflow efficiency and decision-making. Furthermore, rising government and private-sector investments in healthcare digitization and strong distribution networks of key manufacturers are solidifying North America's position as the dominant regional market for angiography equipment.
For example, in October 2024, the Society for Cardiovascular Angiography and Interventions (SCAI), USA, released a consensus document outlining best practices for managing ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI). Published in FSCAI, the guidelines offer actionable recommendations for complex cases and highlight the importance of advanced imaging and support tools in catheterization lab settings.
Future Market Scenario (2025-2032F)
The global angiography equipment market is poised for robust growth, driven by continuous advancements in imaging technologies, increasing demand for minimally invasive procedures, and the growing burden of cardiovascular diseases. Integration of AI and automation in angiographic systems is expected to streamline diagnostics and improve clinical outcomes. Additionally, expanding healthcare infrastructure in emerging economies and rising government investments in cardiovascular care will further accelerate market expansion in the coming years. In March 2024, Siemens Healthineers announced that its CIARTIC Move mobile C-arm, equipped with autonomous mobility features, received FDA clearance. This system enhances workflow in surgical environments by supporting standardized 2D and 3D imaging, making imaging faster and more efficient for medical teams in hospitals and outpatient settings.
Key Players Landscape and Outlook
The key players in the market are significantly investing in the development of angiography equipment and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.
In March 2024, Shimadzu Corporation launched "SHIMADZU Connected," a service-oriented initiative designed for diagnostic X-ray systems. The program aims to create recurring revenue by offering continuous service contracts, spare parts, and licensed software to healthcare providers. Its first product, SMILE guard, proactively replaces X-ray tubes before a malfunction occurs.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.